Neuraly
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
704 Quince Orchard Rd Ste 320, Gaithersb...Phone Number
(301) 658-6100Website
www.neuralymed.comRevenue
$12.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Neuraly
Neuraly is a clinical stage biotechnology company focused on discovering and developing revolutionary treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company aims to create new drugs that target innovative pathways to provide effective therapies for progressive diseases. With a dedicated team of professionals, Neuraly is committed to improving the lives of patients suffering from severe neurodegenerative conditions. Their clinical development strategy emphasizes the inhibition of pathological glial activation to prevent neuronal cell death.Explore more
Neuraly Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuraly your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Neuraly recently announced quarterly report
Product Launch: Get notified when Neuraly launches new products
Neuraly, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Neuraly has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Neuraly had a recent Job posting/layoffs
Check out if Neuraly is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Neuraly
Check if Neuraly has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Neuraly as Masked Content
Find 2 more new buyers
Compare Similar Companies to Neuraly
Compare insights from companies similar to Neuraly, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neuraly
$12.2M
51-200
Private
<$5M
2016
SS
Svetlana SosnovtsevaExecutive Director, Bioanalytical Development
Company Profile Activity
Activity Insights
Neuraly is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neuraly is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neuraly.
Neuraly financials insights
Gather financial insights about Neuraly, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Neuraly Tech Stack
A closer look at the technologies used by Neuraly
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Research & Development, Clinical Systems
Funding
Neuraly has received an SBA PPP loan for $350,000-1 million from Bank of America.
Funding
Neuraly News & Media
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, a clinical-stage biotechnology company pioneering development of disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD). The primary endpoint, change from baseline to Week 36 in the sum of MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Examination) after 36 weeks of NLY01 treatment, compared to placeboNeuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD). NLY01, Neuraly’s lead development asset, is a glucagon-like peptide 1 receptor (GLP-1R) agonist that has been demonstrated to inhibit pathological activation of microglia by binding upregulated GLP-1R in animal models of neurodegenerD&D Pharmatech Raises $51M in Series C Financing to Advance Potential Disease-Modifying Treatments for Neurodegenerative, Fibrotic, and Metabolic Diseases
GYEONGGI-DO, Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech Raises $51M in Series C FinancingNeuraly Announces Publication in Acta Neuropathologica Communications of Preclinical Data Detailing the Neuroprotective Effect of NLY01 in Models of Alzheimer’s Disease
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly Announces Publication of Preclinical Data Detailing the Neuroprotective Effect of NLY01 in Models of Alzheimer’s Disease
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Neuraly
Sign Up For FreeTo access detailed company insights
Neuraly is a clinical stage biotechnology company focused on discovering and developing revolutionary treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company aims to create new drugs that target innovative pathways to provide effective therapies for progressive diseases. With a dedicated team of professionals, Neu... Read More
